NEUTRON ENTERPRISES INC.(NASDAQBB:NTRN) announces accepted appointment of Dr. Uri Sagman to its advisory committee. TORONTO, April 14 /PRNewswire-FirstCall/ -- NTRN recently launched its wholly owned subsidiary Nanosphere Technologies Inc. to bring together world class technology experts to assist, incubate and accelerate emerging technologies with global commercialization potential. Dr. Sagman will be providing strategic counsel on numerous technology in licensing, acquisition and investment opportunities. Dr. Sagman is the co-founder and Executive Director of the Canadian Nano Business Alliance, an association dedicated to the promotion of the nanotechnology sector in Canada. The Canadian Nano Business Alliance has a diverse membership, which includes representation of government agencies, academic centers of excellence, industry and the investment community. Dr. Sagman is cofounder and President of C Sixty Inc, (http://www.csixty.com/). At C Sixty, Dr. Sagman recruited some of the world's leading scientists, including the 1996 Nobel Prize awardee and co-discoverer of fullerenes, to advance the development of fullerene-based technology for biomedical applications. To that end, Dr. Sagman has enlisted a comprehensive R&D network, based at leading academic centers, which include Rice University, UCLA, Columbia University, Dartmouth University, the University of Toronto, Erlangen University in Germany, and the University of Taiwan. Dr. Sagman is the Chairman of GRN Health International Inc., a globally based academic research organization dedicated to medical research and development. Dr. Sagman is currently engaged in the development of strategies for National Nanotechnology Initiative programs in several countries, specializing in the development of paradigms for public and private sector alliances. In addition, Dr. Sagman's efforts are focused on the application of nanotechnology for problems of global scope. Dr. Sagman is a medical oncologist, a fellow of the Royal College of Physicians and Surgeons of Canada, and a fellowship recipient of the Medical Research Council of Canada. He is a recognized researcher in the field of clinical oncology, tumor biology and immunology. Dr. Sagman obtained his training at McGill University, The University of Calgary, The University of Toronto and Oxford University. Dr. Sagman is the recipient of numerous awards and citations including the Young Investigator awards of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). He has organized and participated as keynote speaker at numerous nanotechnology-based conferences. Dr. Sagman has been extensively profiled in numerous journal and press publications, including Time Magazine, Newsweek, the Economist, the New York Times, Red Herring, Technology Review, Chemical Engineering, the National Post, the Houston Chronicle, and The Toronto Star amongst others. About Neutron Enterprises Inc.: Neutron Enterprises Inc. is a publicly traded venture capital and private equity buyout firm that seeks to continuously acquire technology and businesses through three distinct divisions. University Medical Enterprises Inc. accelerates emerging medical applications and therapeutic molecules in the areas of oncology and cardiology. Nanosphere Technologies Inc. invests in nano technologies and materials companies in the life sciences, fibre optic, semiconductor, energy, chemical and defense industries. Life Sciences Private Equity Inc. seeks to invest in and acquire established product and service health care businesses generating positive free cash flow from operations. This press release does not constitute an offer to sell or a recommendation to purchase any securities. This press release may contain forward-looking statements, including the company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, the successful execution of the company's plan of operation, changes in the company's anticipated earnings, continuation of current contracts, changes in drug approval and other applicable regulations, and other factors detailed in the company's filings with the Securities and Exchange Commission, including its most recent Form 10-QSB Quarterly Reports. In addition, the factors underlying company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public. DATASOURCE: Neutron Enterprises, Inc. CONTACT: Russell J. Hoffman, (914) 924-0365

Copyright